A. Gülfe

发表

Patient‐Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics‐Treated Patients With Rheumatoid Arthritis

L. Kristensen, J. Söderling, J. Wallman, 2018, Arthritis care & research.

EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden

L. Kristensen, J. Wallman, A. Gülfe, 2016, Arthritis Research & Therapy.

L. Kristensen, J. Wallman, A. Gülfe, 2018 .

Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis

B. Månsson, D. Heinegård, P. Geborek, 2001, Annals of the Rheumatic Diseases.

Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.

P. Geborek, T. Saxne, M. Kapetanovic, 2007, Rheumatology.

Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort

H. Bliddal, P. Geborek, T. Saxne, 2014, Arthritis care & research.

Recurrent fever caused by Candidatus Neoehrlichia mikurensis in a rheumatoid arthritis patient treated with rituximab.

C. Wennerås, G. Jönsson, T. Saxne, 2015, Rheumatology.

Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register

P. Geborek, T. Saxne, L. Kristensen, 2007 .

Swedish Arthritis Treatment Group Register psoriatic arthritis patients: Results from the South Efficacy and tolerability of anti-TNF therapy in

P. Geborek, T. Saxne, L. Kristensen, 2007 .

Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties

A. Gülfe, A. Stefánsdóttir, Ylva Borgas, 2019, BMC Musculoskeletal Disorders.

Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden

P. Geborek, L. Kristensen, A. Gülfe, 2009, The Journal of Rheumatology.

Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures

P. Geborek, A. Gülfe, E. Berthold, 2013, Acta orthopaedica.

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

C. Turesson, L. Jacobsson, P. Geborek, 2005, The Journal of rheumatology.

Measure for measure. Outcome assessment of arthritis treatment in clinical practice

A. Gülfe, 2009 .

Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden

P. Geborek, T. Saxne, I. Petersson, 2010, Arthritis care & research.

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.

P. Geborek, T. Saxne, M. Kapetanovic, 2007, Rheumatology.

National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients

M. Neovius, P. Geborek, T. Saxne, 2011, Annals of the rheumatic diseases.

Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden

L. Jacobsson, P. Geborek, T. Saxne, 2009, Annals of the rheumatic diseases.

No increase of severe infections in RA patients treated with TNF-blockers

C. Turesson, L. Jacobsson, P. Geborek, 2005 .

Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents

P. Geborek, T. Saxne, D. Aletaha, 2009, BMC musculoskeletal disorders.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

H. Olsson, C. Turesson, P. Geborek, 2005, Annals of the rheumatic diseases.

Response criteria for rheumatoid arthritis in clinical practice: how useful are they?

P. Geborek, T. Saxne, A. Gülfe, 2005, Annals of the rheumatic diseases.

Study from Southern Sweden Necrosis Factor Blockade in Rheumatoid Arthritis : An Observational Cohort Six and 12 Weeks Treatment Response Predicts Continuation of Tumor

P. Geborek, L. Kristensen, A. Gülfe, 2009 .

National EQ-5 D tariffs and quality-adjusted life-year estimation : comparison of UK , US and Danish utilities in south Swedish rheumatoid arthritis patients

M. Neovius, P. Geborek, T. Saxne, 2022 .

Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden

L. Jacobsson, P. Geborek, T. Saxne, 2009, Annals of the rheumatic diseases.

What PASSes for good? Experience-based Swedish and hypothetical British EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable symptom state cut-off values in chronic arthritis patients on TNF blockade

A. Gülfe, J. Wallman, A. Cooper, 2016, Scandinavian journal of rheumatology.

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

P. Geborek, T. Saxne, A. Gülfe, 2007, Annals of the rheumatic diseases.